Emerging role of immunotherapy in urothelial carcinoma—Immunobiology/biomarkers
- 1 December 2016
- journal article
- review article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 34 (12) , 556-565
Abstract
No abstract availableKeywords
This publication has 86 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1Cancer Research, 2012
- Type I interferon is selectively required by dendritic cells for immune rejection of tumorsJournal of Experimental Medicine, 2011
- Engineered T cells for pancreatic cancer treatmentHPB, 2011
- Intrinsic and extrinsic control of peripheral T‐cell tolerance by costimulatory molecules of the CD28/ B7 familyImmunological Reviews, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical TrialClinical Cancer Research, 2010
- Costimulatory and coinhibitory receptors in anti‐tumor immunityImmunological Reviews, 2009
- CTLA-4 blockade increases IFNγ-producing CD4 + ICOS hi cells to shift the ratio of effector to regulatory T cells in cancer patientsProceedings of the National Academy of Sciences, 2008
- CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinomaProceedings of the National Academy of Sciences, 2007